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Abstract: In developed, developing and low-income countries alike, type 2 diabetes mellitus (T2DM)
is one of the most common chronic diseases, the severity of which is substantially a consequence
of multiple organ complications that occur due to long-term progression of the disease before
diagnosis and treatment. Despite enormous investment into the characterization of the disease, its
long-term management remains problematic, with those afflicted enduring significant degradation
in quality-of-life. Current research efforts into the etiology and pathogenesis of T2DM, are focused
on defining aberrations in cellular physiology that result in development of insulin resistance and
strategies for increasing insulin sensitivity, along with downstream effects on T2DM pathogenesis.
Ongoing use of plant-derived naturally occurring materials to delay the onset of the disease or
alleviate symptoms is viewed by clinicians as particularly desirable due to well-established efficacy
and minimal toxicity of such preparations, along with generally lower per-patient costs, in comparison
to many modern pharmaceuticals. A particularly attractive candidate in this respect, is fenugreek,
a plant that has been used as a flavouring in human diet through recorded history. The present
study assessed the insulin-sensitizing effect of fenugreek seeds in a cohort of human volunteers, and
tested a hypothesis that melanin-concentrating hormone (MCH) acts as a critical determinant of
this effect. A test of the hypothesis was undertaken using a hyperinsulinemic euglycemic glucose
clamp approach to assess insulin sensitivity in response to oral administration of a fenugreek seed
preparation to healthy subjects. Outcomes of these evaluations demonstrated significant improvement
in glucose tolerance, especially in patients with impaired glucose responses. Outcome data further
suggested that fenugreek seed intake-mediated improvement in insulin sensitivity correlated with
reduction in MCH levels.
Keywords: hyperinsulinemic euglycemic glucose clamp (HEGC); fenugreek; melanin-concentrating
hormone (MCH); RIA; type 2 diabetes; clinical pilot study
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1. Introduction
1.1. Major Pathologic Features of T2DM
Type 2 diabetes mellitus, T2DM or NIDDM (non-insulin-dependent diabetes mellitus) is a
metabolic disorder characterized by hyperglycemia, insulin resistance and relative insulin deficiency.
Its primary pathomechanism is persistent hyperglycemia, due to inability of a subject’s cells to induce
adequate metabolic responses to insulin produced by pancreatic β islet cells. A major feature of the
disease is the inability of an individual’s insulin to maintain normoglycemia. Major consequences
occurring due to reduced insulin sensitivity by tissues for which glycemic balance is particularly
important, such as adipose tissue muscles, liver, may be very severe [1–6].
1.2. Mechanisms Contributing to T2DM Onset And Progression
T2DM is often associated with obesity and pathologically altered lipid metabolism [7]. The
pathogenesis of the disorder also involves aberrant alteration in levels and function of many centrally or
peripherally acting hormones and peptides, including: insulin, leptin, ghrelin, glucagon-like peptide-1
(GLP-1), melanin-concentrating hormone (MCH) and many others. T2DM is the most common form of
diabetes with a proportion of 90–95% compared to T1DM [8]. Its incidence is gradually growing, and
professionals and organizations, including the World Health Organization (WHO) and the American
Diabetes Association predict that by 2030 we will face a kind of “diabetes epidemic” [2,4,9–11].
1.3. Countermeasures to T2DM Progression
This diabetic condition usually can be controlled by lifestyle changes, including general diet, use
of dietary supplements and/or oral antidiabetic agents [12–15]. The objective of these strategies,
which is to normalize blood glucose, is increasingly aided by identification of agents based on
generally regarded as safe (GRAS) plant materials, some of which, such as fenugreek (Trigonella
foenum graecum/TFG), are generally widely represented in the human diet. Fenugreek is one of
the oldest medicinal plants, endemic to India and North Africa [16,17]. Currently it is widely
cultivated worldwide, especially in the Mediterranean region. Both seeds and leaves of fenugreek
are widely used as a culinary spice (to enhance the taste of many meat or vegetable dishes) [18,19].
The seeds are used as a therapeutic supplement for numerous indications: as an appetite stimulant,
to treat digestive disorders, to increase milk production in lactating women and treatment of
hyperlipidemia and diabetes [20,21]. The major bioactive components of fenugreek seeds include:
alkaloids, amino acids, flavonoids, fibers, coumarin, lipids, vitamins, minerals, notable saponins and
steroidal sapogenins, of which those of most intensive interest, are yamogenin and diosgenin [16,22,23].
Fenugreek seeds possess well known therapeutic effects, the most important of which include
their antidiabetic activity, related regulation of food intake and mood disorders. They additionally
exhibit antioxidant, hypolipidemic, cardioprotective and gastroprotective effects, immunoregulatory,
antimicrobial, anti-inflammatory activities and analgesic properties. Moreover, recent studies of
the seeds demonstrate that their components are agonists on the MCHR1 isoform of MCHRs
(melanin-concentrating hormone receptor) [18,24–27].
1.4. MCH Properties
MCH is a cyclic peptide that was first isolated and purified from salmon pituitary gland and
structurally characterized by Kawauchi et al., in 1983 [28]. Originally, its primary biological function
was considered to be skin paling in fish [29,30]. Further investigation revealed mammalian MCH
expression, with potential for a diverse range of functions. In mammals, MCH is a nonadecapeptide
produced in the hypothalamus and secreted predominantly in neurons of the lateral hypothalamic
area (LHA) and zona incerta (ZI) in the subthalamus. Moreover, its presence has been demonstrated in
peripheral tissues, including pancreatic β-cells, colonic epithelial cells and adipocytes [31–36].
Int. J. Mol. Sci. 2018, 19, 771 3 of 17
1.5. MCHR Distribution and Major Activities
The effects of MCH are mediated by two receptors belonging to the G-protein-coupled receptor
family: MCH-R1 and MCH-R2 [30]. Expression of MCH-R1 is the highest in the ventromedial
and dorsomedial nuclei of the hypothalamus, and both appear to be regulators of food intake [37].
Additional roles for these hormones have been shown in diabetes, obesity, and gastrointestinal
and mood disorders. In most sources, this isoform exhibits approximately 38% homogeneity with
MCH-R1 [29,30,38]. The biological function of MCH-R2 remains undefined at the time of this writing,
but its wide expression in the brain and expression patterns in peripheral tissues, suggest diverse
regulatory functions [39,40]. Investigation of this molecule has additionally revealed that MCH-R2
expression is different than that of the MCH-R1 isoform in certain areas of the brain, including
olfactory tissue, nucleus accumbens, amygdala along with hippocampal, hypothalamic cells. MCH-R1
expression is typically limited to the cortical area of the brain and it is not present in the periphery [41].
1.6. Differential Effects of MCH and Relevance to Diabetes Research
Accordingly, stimulation of each of these two isoforms is expected to have differential effects on
neurologic function and downstream effects (that may possibly be in the opposite direction) [41,42].
MCH thus appears to be an important mediator of metabolic processes, food intake, energy expenditure,
obesity, mood control, stress and sleep-wake cycles. Intriguingly, in the context of the investigation
described by this report, recent studies have demonstrated a role for MCH in the regulation of
pancreatic beta-cell function [43–47], findings which led the authors of this report to speculate that
bioactive components of fenugreek seeds may exert medically useful effects on these processes.
1.7. Objectives of Present Investigation
The study described in the present report was undertaken to evaluate a hypothesis that an orally
administered preparation of fenugreek seeds reduces hyperglycemia through insulin sensitization.
The investigation further assessed the safety and tolerance of repetitive short interval administration
of fenugreek seed preparation for a given subject during a ten-day period. A corollary hypothesis
tested in the present study is that melanin-concentrating hormone (MCH) is a critical component of
T2DM-associated changes in insulin sensitization.
2. Results
2.1. Fasting Serum Glucose Levels in Placebo- and Fenugreek-Treated Subjects
To adjust the rate of glucose infusion, it was necessary to determine the fasting blood glucose
levels. As expected, there were no statistically significant differences in the fasting serum glucose
levels among the fenugreek- or placebo-treated groups (Figure 1).
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glucose infusion rate significantly increased among the fenugreek-treated volunteers, referring to 
the insulin-sensitizing effect of the TFG (Table 1 and Figure 3). It is notable that GIR values of the 
TFG-treated group were significantly lower at the baseline point (before the initiation of the 
treatment). Although, patients were randomly divided into groups, two subjects with diminished 
GIR were sorted to the TFG group, as it turned out during the HEGC procedure. Interestingly, 
TFG-treatment exerted the most powerful effect in these two cases (increasing GIR up to 100%). 
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Figure 1. Fasting serum glucose levels in the placebo- and fenugreek-treated subjects. No significant
differences were found among groups.
2.2. Fasting Plasma Insulin Levels of the Placebo- and Fenugreek-Treated Subjects
Determining the fasting insulin level is necessary to calculate derived parameters and also for the
safe execution of HEGC procedure. The baseline insulin levels were in the normal ranges for all of the
volunteers, and no significant differences were found between the fasting plasma insulin levels of the
fenugreek- and placebo-treated groups (Figure 2).
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Figure 2. Fasting plasma ins li l l f the placebo- and fenugreek-treated subjects.
2.3. Effects of TFG on Glucose Infusion Rate ( IR)
During the hyperinsulinemic euglycemic glucose clamp (HEGC) examination, the steady-state
glucose infusion rate significantly increased among the fenugreek-treated volunteers, referring to
the insulin-sensitizing effect of the TFG (Table 1 and Figure 3). It is notable that GIR values of the
TFG-treated group were significantly lower at the baseline point (before the initiation of the treatment).
Although, patients were randomly divided into groups, two subjects with diminished GIR were sorted
to the TFG group, as i turn d u during the HEGC procedure. Interestingly, TFG-treatment exerted
the most powerful effect in these two cases (increasing GIR up to 100%).
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Table 1. (A) Influence of TFG (Trigonella foenum graecum) on GIR (Glucose Infusion Rate) in the placebo-
and fenugreek-treated subjects. ** represents statistically significant difference (p < 0.01) compared to
the Day 1 TFG group; (B) Individual GIR values of volunteers in Placebo and TFG-treated group. GIR
is expressed as mg/kg/min.
(A)
Summary GIR (mg/kg/min) GIR (mg/kg/min) GIR (mg/kg/min) GIR (mg/kg/min)
Day 1
(Placebo, n = 5)
Day 11
(Placebo, n = 5)
Day 1
(TFG, n = 8)
Day 11
(TFG, n = 8)
Mean 8.45 8.5 6.63 8.13 **
S.D. 3.07 2.86 3.65 3.01
(B)
Individual GIR Day 1(Placebo, n = 5)
Day 11
(Placebo, n = 5)
Day 1
(TFG, n = 8)
Day 11
(TFG, n = 8)
1. 4.99 5.79 6.49 7.46
2. 6.99 6.69 2.04 4.86
3. 12.34 12.23 6.05 8.09
4. 7.0 6.9 4.39 6.96
5. 10.95 10.87 2.52 4.14
6. 10.09 10.84
7. 12.14 13.02
8. 9.34 9.45
Mean 8.454 8.496 6.633 8.125
S.D. 3.065 2.86 3.645 3.005
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Figure 3. GIR in the placebo- and fenugreek-treated subjects. ** refers to statistically significant
difference (p < 0.01) between Day 1 and Day 11 in the treated group.
2.4. Serum Lipid Levels of the Placebo- and Fenugreek-Treated Subjects
Figure 4 represents our results showing no statistically significant differences in the serum lipid
parameters (total cholesterol, triglycerides, low-density lipoprotein (LDL) and high-density lipoprotein
(HDL)-cholesterol) of the fenugreek- and placebo- treated groups.
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2.5. Calculated Parameters of Insulin Sensitivity Assessment (MCRI, ISI, QUICKI, HOMA-IR and
HOMA-%β) in the Placebo- and Fenugreek-Treated Subjects
MCRI (metabolic clearance rate of insulin), ISI (insulin sensitivity index), QUICKI (quantitative
insulin sensitivity check index), HOMA-IR (homeostatic model assessment-insulin resistance) or
HOMA-B (homeostatic model assessment-beta-cell function) indices were calculated to precisely
assess insulin sensitivity. Our results presented in Figures 5–8, show that no statistically significant
difference could be observed in the values f t e a e entioned indices between the fenugreek-
and placebo-treated groups. t te insulin levels used for calculations are presented in
Supplementary Material section (Supple e t f t is paper.
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2.6. Effect of TFG on Plasma MCH Levels
Plasma MCH concentrations were measured by a highly specific and sensitive radioimmunoassay
(RIA) ethod developed recently by our team, as is described in Section 4.8. Our assumption is
partially confirmed by the fact that after ten days of Fenugreek treatment, plasma MCH concentration
was significantly reduced in the TFG-treated group, when measured prior to HEGC (0 min sample).
On the contrary, no sta istically significant di fer nces were found in the MCH plasma concentrations
after 120 min of the HEGC procedure, as shown in Figure 9.
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Figure 9. MCH (melanin-conce trating hormone) l vels of the placebo- and fe ugreek-treated subjects.
* represents significant difference (p < 0.05) between Day 1 and Day 11 in the treated group.
2.7. Correlation between MCH and Serum Lipid Levels
Analyzing the relationship between plasma MCH concentration and serum lipid levels of
fenugreek-treated volunteers, we observed that elevation of plasma MCH level may be associated with
a decreasing concentration of total cholesterol, including LDL- and HDL-cholesterol, and although the
differences do not reach the level of statistical significance, a clear tendency can be seen (Supplementary
Tables S1 and S2). In parallel, we showed a negative correlation between the MCH and triglyceride
levels. Data is presented in Supplementary Material, in Supplementary Tables S1 and S2.
2.8. Correlation between MCH and Serum Glucose Levels
Analyzing the correlation bet ee t e eripheral expression of MCH and serum glucose
concentrations we did not observ i tically significant association between the MCH and
glucose l vels in placebo- and fenugre l nteers (data in Su plementary Table S3).
2.9. Correlation between MCH and Plas li evels
Our results indicate that no stati i nificant co relation could be det cted between the
MCH and insulin plasma concentrati ted in Su plementary Table S4).
3. Discussion
Outcomes of the experiments conducted in the present investigation demonstrate that fenugreek
seed does indeed exhibit insulin-sensitizing effects in tissues. Evidence for this conclusion is based on
observations that glucose infusion rate (GIR) values significantly increased in participating subjects,
following ten-day treatment periods with fenugreek seed preparations (p = 0.001327). The largest
increases in GIR, corresponding to an insulin sensitizing effect of 97%, occurred in two patients with
the lowest GIR values in the test group, measured before initiation of treatment. GIR increases were
also observed in the other six volunteers treated with fenugreek capsules, however, to a much lesser
extent than in the two subjects with the lowest measured GIRs. In contrast, placebo-treated subjects,
failed to exhibit significant change in GIR values. According to the abovementioned findings, we may
conclude that the TFG-treatment is more effective when the patient is insulin-resistant, and that it does
not have influence on glucose homeostasis under normal, physiological conditions. Additionally, no
significant placebo-associated changes were observed in MCRI, QUICKI, ISI, HOMA-IR, and HOMA-B,
serum glucose, plasma insulin and serum lipids. Interpretation of these d ta is, nevertheless, subject to
the caveat that the present study is a preliminary analysis of fenugreek seed effects and not intended
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as a definitive analysis of T2DM pathomechanism. Here, the sample ‘n’ for test subjects is low, and it
is anticipated that more comprehensive future studies will involve participation of larger groups of
volunteers. Nevertheless, results of this small pilot study are encouraging, since safety and efficacy
of fenugreek seeds have been proven in human subjects, with parallel changes in the plasma level of
MCH, a mediator that may play an important role in glucose-homeostasis. Future clinical and basic lab
analyses of this biomaterial, planned by the authors, will extend the experiments described here into
detailed characterization of signaling processes contributing to insulin sensitization that are sensitive to
modulation by fenugreek and other natural products. Such investigations will be conducted in tandem
with evaluations of currently available insulin-sensitizing drugs to determine the capability of natural
substances, to potentiate their pharmacological value and reduce occurrence of side effects. Haines
et al. have previously conducted product development research that achieved these objectives [48].
A major outcome of the present study included an observation that following ten days of fenugreek
seed ingestion, serum MCH levels were significantly reduced (p = 0.0464), while no such reduction
was observed in the placebo-treated group. These results demonstrate that fenugreek-mediated
augmentation of insulin sensitization and improved glucose metabolism correlate with and may be
substantially dependent on decrease of MCH levels. The MCH is involved in several physiological
functions in vertebrates. Evidence suggests its crucial role in energy homeostasis, food intake, obesity
and T2DM. The increased levels of MCH is correlated with hyperphagia, body weight gain, increased
white adipose tissue and liver mass, reduce brown adipose tissue function, moreover, elevated
MCH may produce hyperglycemia, hyperinsulinemia, and hyperleptinemia [49–54]. On the contrary,
MCH-knockout mice are lean and resistant to obesity, furthermore, resistant to age-related glucose
intolerance [55]. In the periphery, MCH was detected in several tissues, e.g., in the beta cells of the
pancreatic islets, adipose tissues and in the duodenum. MCH induces islet hyperplasia, which suggest
that it may regulate pancreatic islet secretory function and beta cell dynamics [35,36,56,57]. Moreover,
Pereira-da-Silva et al. suggested that MCH may act as the central modulator of insulin activity,
as it could modify glucose metabolism [45]. MCH-containing neurons and MCH receptors have a
critical role in energy homeostasis. These (second order and downstream) neurons regulated by POMC
(proopio-melanocortin) and NPY/AGRP (neuropeptide Y/agouti-related peptide) (first-order) neurons
and modulate food intake. First order neurons can process the signals arriving from the periphery
like ghrelin, insulin and leptin. NPY/AGRP will stimulate and POMC will inhibit MCH-containing
neurons. Ghrelin act as a positive modulator on NPY/AGRP; thus, if the MCH levels will increase,
food intake will be enhanced. Effects of insulin and leptin are antagonistic, whereby POMC neurons
will be stimulated by these hormones, thus, MCH-containing neurons will be inhibited and food
intake will decrease. MCH-containing neurons are negatively affected by autoregulation as well [58].
Furthermore, MCH-containing neurons not only secrete MCH, but also produce GABA (gamma-amino
butyric acid), CART (cocaine- and amphetamine-regulated transcript) and nesfatin. These neurons can
be directly activated by orexinergic neurons, and indirectly by glutamate release from excitatory fibers.
In contrast, MCH inhibits orexinergic neurons and the neighboring GABAergic fibers. Furthermore,
MCH-containing neurons may be inhibited by MCH, GABA, NE (norepinephrine, mediated by alpha-2
receptors), serotonin, acetylcholine (muscarinic), neuropeptide Y and histamine [59]. Interestingly,
Hausen et al. found that insulin can act directly on MCH-containing neurons, which resulted in
impairment of locomotor activity and insulin sensitivity [60]. This is a reasonable interpretation of the
data, since elevated levels of the hormone are associated with increase in the food intake and, thus,
body weight, and with an increased rate of preadipocyte differentiation [61].
To investigate the correlation between the MCH and glucose, as well as lipid metabolism,
we measured the blood levels of the correspondent parameters. Although literature data presents
an important decrease in the aforementioned blood parameters after fenugreek treatment, it is
important to highlight the major differences between these study designs and our experimental
concept. Accordingly, numerous experimental and clinical reports are available, but all enrolled
patients with impaired glucose tolerance, prediabetes or manifest T2DM, while in our study, only
Int. J. Mol. Sci. 2018, 19, 771 10 of 17
healthy volunteers were examined [8,62,63]. Another important difference was that our volunteers
were treated with a lower daily dose of TFG, 3 g/day instead of 10 g/day used by others [8,62,63].
Finally, we treated the volunteers only for ten days, in particular interest to short-term effects of
TFG-treatment [8,62,63]. Probably due to these differences, we failed to find significant changes in
fasting glucose, insulin or serum lipid concentrations. However, to our knowledge, this is the first
study to demonstrate that fenugreek seeds may contribute to the regulation of glucose metabolism by
restoring the insulin sensitivity of peripheral tissues, shown by the most sensitive method (HEGC) on
human volunteers. Moreover, we observed that the fasting insulin level is higher in the TFG-treated
group at the end of the study, probably due to the insulinotropic effect of the fenugreek seeds [64–66].
Another novel finding is that MCH-like immonoreactivity, measured by a highly specific method
developed by our team, increased significantly in the treated group after ten days of treatment, when
measured from blood samples at the 0 time point, before HEGC was carried out. This difference
was blurred away when measuring MCH levels after the HEGC procedure, nevertheless, a possible
explanation could be that serum levels of MCH—which is an orexigenic hormone responsible for energy
homeostasis—alter when glucose is administered during the HEGC procedure. We consider baseline
levels more reliable, and the decrease observed in the treated group is more convincing, especially
if we count the fact that fasting increases MCH serum levels, as was shown by Gavrila et al. [31].
According to the preliminary results shown here, we conclude that it would be valuable to investigate
effects of TFG on MCH levels in a larger number of patients who manifest T2DM. MCH-related signal
transduction pathways could become new molecular targets of drug discovery and development in
the future.
4. Experimental Section
4.1. Study Design
The study was a double-blind, multiple-dose, randomized, placebo controlled, single treatment
period pilot study, entitled: “A pilot clinical study in healthy volunteers of the ten days multiple dose
(three times daily 1000 mg) administration of Fenugreek capsules (the Hungarian product: Dr. Makai
Görögszénamag) to evaluate the suspected insulin sensitizing effect behind the glycemic control of the
treatment well-established in animal and human trials (Pilot study)”. The study was conducted at the
Clinical Pharmacology Department at the University of Debrecen in the period 31 January–20 February
2017 and was sponsored by Libafood-Tech KFT Hungary (Debrecen, Hungary).
4.2. Ethical Considerations
The Clinical Study Protocol was authorized by the National Office of the Chief Medical
Officer (Hungary) (IF-911-2/2017, dated: 11 January 2017) based on the Ethical Approval of the
Medical Research Council—Scientific Research Ethics Committee (Hungary) of 9 January 2017
(ETT TUKEB: 1930-1/2017/EKU). The protocol was performed in compliance with International
Council on Harmonization (ICH) Guidelines for Good Clinical Practices, and with the principles of the
Helsinki Declaration.
4.3. Subject Recruitment
The volunteers enrolled in the study were recruited from students, employees of the University
and outsiders based on a preliminary screening test. The patients were informed before the study
orally and in a written form at a volunteer meeting and every volunteers signed the ICFs. Within
21 days prior to the start of the clinical study, the volunteers were taken under physical and ECG
examination, respectively. Routine clinical laboratory tests, including Human Immunodeficiency Virus
(HIV), Hepatitis B Virus Surface Antigen (HBsAG), drugs of abuse and pregnancy tests were also
performed. Thirteen volunteers were enrolled in this pilot study: 6 males and 7 females, of which
2 males in Placebo and 4 males in TFG-treated group, accordingly 3 females in Placebo and 4 females
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in TFG-treated group. The age of the volunteers ranged from 23 to 55 years (Mean = 30.07, SD = 10.06).
In the Placebo group the age of probands ranged from 23 to 37 years (Mean = 28.00; SD = 5.57) and in
the TFG treated group from 31 to 55 years (Mean = 42.75; SD = 8.86). The BMI of the volunteers ranged
between 19.89 and 31.62 (Mean = 25.80). In the Placebo group the BMI of probands ranged from 19.89
to 28.76 (Mean = 23.75; SD = 3.38) and in the TFG treated group from 22.68 to 31.62 (Mean = 27.08;
SD = 2.07). The acceptance of volunteers was based on the inclusion and exclusion criteria, and
were randomly separated into placebo (5) and treatment (8) groups using a computer-generated
randomization code.
4.4. Inclusion and Exclusion Criteria
Healthy, non-smoker and non-pregnant, 18–60 years old volunteers, with BMI (body mass index)
= 18.5–30 kg/m2, normal ECG and vital signs were included. Patients with asthma, allergic reactions,
cardiovascular, respiratory, kidney, liver, endocrine and neurological diseases or psychiatric disorders
in the medical history were excluded from the study. Other exclusion criteria included smoking,
alcoholism, pregnancy, lactation, viral infections, medical therapy in the last 2 weeks, participation in
another clinical study in the last 30 days.
4.5. Used Products
Test product: Dr. MAKAI Fenugreek, with active ingredient: Trigonella foenum-graecum,
in 500 mg hard gelatin capsule. (Manufactured by: Trigonella MED Ltd., Mosonmagyaróvár, Hungary,
OÉTI number: 6698/210, Expiry date: 31 August 2017).
Placebo product: Placebo, without active compound (filled with grits) in hard gelatin capsule
(Manufactured by: Trigonella MED Ltd., Mosonmagyaróvár, Hungary).
For 10 days (from day 1 to 11) test or placebo product was self-administered by the subjects,
2 capsules p.o., three times a day. On the first day of the study, 2 capsules were administered, but only
at noon and in the evening, while on the last day, 2 capsules were administered, only in the evening.
4.6. Hyperinsulinemic Euglycemic Glucose Clamp (HEGC)
The HEGC is considered the gold standard for the determination of insulin secretion and
resistance. The method was described by DeFronzo et al. in 1979 [67] and was performed to estimate
the whole body insulin sensitivity of the volunteers. The test was carried out on the first day prior to
the treatment, and after 10 days of TFG or placebo treatment, on the eleventh day. Before HEGC, body
weight and height recording and blood sampling for clinical chemistry—including insulin and MCH
determination—was carried out. The principle of the method was to maintain euglycemia at clamped
hyperinsulinemia. The average Glucose Infusion Rate (GIR), expressed in mg/kg/min necessary to
compensate the hypoglycemic effect of the continuous insulin infusion is the accepted measuring unit
for determining tissue insulin sensitivity.
All studies were performed at 7.00 a.m., after a 12 h overnight starvation. Two peripheral veins
were cannulated for both forearms: one antecubital vein to administer the continuous glucose and
insulin infusions, and one forearm vein on the contralateral arm for blood sample collection.
Insulin infusion was prepared as follows: in a 50 mL syringe, 48 mL of physiological saline, 8×
BSA units of Humulin R, Eli Lilly insulin, and 2 mL of the volunteer’s own blood (to prevent insulin
adhesion) were homogenized and administered via a precision perfusion pump to the volunteers.
The priming infusion rate was 60 mL/h for 4 min, then 30 mL/h for further 4 min, followed by
a maintenance rate of infusion that was 15 mL/h (corresponding to 40 mU/m2/min of insulin)
administered for 112 min. The rate of the 20% dextrose infusion was adjusted to maintain the target
blood glucose levels at 5.5 ± 0.5 mmol/L (euglycemic range).
Blood glucose levels were determined every 5 min using Accu-Check blood glucose meter
(Accu-Check, Roche Diagnostics, Budaörs, Hungary), utilizing the glucose oxidase method, and the
glucose infusion rate was adjusted according to the blood glucose level.
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In a “steady state” condition, that is set during HEGC, usually in the 90th minute, the blood
glucose levels are stabilized, so the rate of glucose infusion no longer requires modification, or needs
to be minimally adjusted. The steady state glucose infusion rate (in the last 30 min) was used to
characterize insulin sensitivity [67].
After cessing the insulin infusion, the volunteers were strictly monitored, blood glucose levels
were checked, and glucose infusion was administered in case of necessity.
An intensive care expert team was ready to treat any unwanted effects with special regards to
events at risk of hypoglycemia during and following the glucose clamping.
Following HEGC, post-study laboratory investigations were performed within 24 h after the last
treatment phase, and there was a closing visit after 30 days.
4.7. Analytical Methods
The laboratory parameters, including the liver function tests, kidney function tests, electrolyte
determinations, hematology, urinalysis, fasting glucose and insulin (0 min), repeated glucose and
insulin (60 min, 90 min, 120 min) determinations were performed by the Department of Laboratory
Medicine, University of Debrecen.
The MCH concentration was determined from blood samples separately taken into 10 mL EDTA
(ethylenediamine-tetraacetic acid)-containing tubes, at 0 and 120 min on the 1st and the 11th days using
a novel MCH radioimmunoassay developed by the researchers of the Department of Pharmacology
and Pharmacotherapy, University of Debrecen.
4.8. Measurement of Melanin-Concentrating Hormone
The EDTA-tubes were centrifuged (4000 rpm, 4 ◦C, 15 min), and the supernatants were further
processed for radioimmunoassay (RIA) analysis of MCH-like immunoreactivity (MCH-LI). The
collected plasma samples were stored at −80 ◦C until RIA determination.
Due to the low circulating levels of MCH in plasma, a minimum of 1 mL plasma was required for
the accurate determination by radioimmunoassay. Collected plasma samples were thawed, and during
extraction procedures, samples and extraction reagents were stored in an ice water bath. Extraction
was performed in the polypropylene RIA tubes (5 mL, 12 × 75 mm). For precipitation of plasma
proteins, 1 mL plasma was added to 3 mL 96% ethyl alcohol. After mixing, the samples were incubated
in an ice bath for 30 min. After centrifugation (4000 rpm, 4 ◦C, 10 min) the supernatants were decanted
into RIA tubes and evaporated to dryness using nitrogen stream without heat. The dried samples
were stored at −80 ◦C prior to RIA determination. In the RIA process the samples were re-dissolved
in 800 µL assay buffer and assayed directly in these tubes. In our RIA examination MCH specific
antiserum (MCH1/5) was applied, which was raised against a conjugate of rat MCH and bovine serum
albumin (BSA) coupled by glutaraldehyde in rabbits. Rat MCH peptide was used as a RIA standard.
The range of concentration was between 0 and 200 fmol/mL. Mono-125I-labeled MCH was applied as
a RIA tracer prepared in our isotope laboratory. Our assay buffer (0.05 mol/L, pH 7.4 phosphate buffer)
contained 0.1 M NaCl, 0.05% NaN3, 0.25% bovine serum albumin (BSA, Sigma-Aldrich, St. Louis, MO,
USA). The 1 mL incubation mixture contained 100 µL MCH standards, 100 µL antiserum (working
dilution 1:3500), 100 µL RIA tracer (3000 cpm/tube) and the assay puffer. After 48 h incubation at 4 ◦C
the antibody-bound peptide was separated from the free peptide by addition of 100 µL separating
suspension (10 g charcoal, 1 g dextran and 0.5 g commercial fat-free milk powder in 100 mL distilled
water). After centrifugation (4000 rpm, 4 ◦C, 20 min) the tubes were gently decanted. Radioactivity of
the precipitates was measured in a NZ310 type gamma counter (Gamma, Budapest, Hungary). The
MCH-LI of the unknown samples was read from the calibration curve.
Antiserum “MCH1/5”, used in the assay turned out to be C-terminal specific without affinity
for the structurally similar peptides. The average ID50 value of the calibration curves was
11.93 ± 1.78 fmol/mL, determined in ten consecutive assays. Detection limit of the assay for rat
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MCH was 0.2 fmol/mL. Intra-assay and inter-assay coefficients of variation were 6.84% and 9.32%,
respectively [35].
4.9. Assesment of Insulin-Sensitivity
Based on the raw data obtained using the HEGC method we can calculate the GIR, the metabolic
clearance rate of insulin (MCRI), the insulin sensitivity index (ISI) and the quantitative insulin
sensitivity check index (QUICKI) that are indicators of the whole body insulin sensitivity [68–70].
Formulas for calculations:
GIR = glucose infusion rate [(µL/min)/BW (body weight in kg) × 100] × (20 × 10)
MCRI = (insulin infusion rate/steady state plasma insulin concentration − basal plasma insulin
concentration) × 1000, expressed in mU/m2/min.
ISI = (glucose infusion rate/steady state plasma insulin concentration) × 100, expressed in
mg/kg/min/mU/mL.
QUICKI = 1/logInsuline(0 min) (µIU/mL) + logGlucose(0 min) (mg/dL).
To estimate insulin resistance and pancreatic β-cell functions we used the widely approved
homeostatic model of assessment [69–73].
The HOMA-IR (HOMA for insulin resistance) = (FPI × FPG)/22.5 and the HOMA-B (HOMA of
β-cell function) = (20 × FPI)/(FPG − 3.5) were calculated as proposed by [72,74], where FPI = fasting
plasma insulin (µIU/mL) and FPG = fasting plasma glucose (mmol/L).
4.10. Data Analysis and Statistics
Statistical analysis was carried out using the SAS system, version 9.2 (SAS Institute, Cary, NC,
USA). The safety laboratory parameters were statistically analyzed by repeated measures ANOVA.
The efficacy parameter for insulin sensitivity (GIR) for the fenugreek and placebo treatment groups
was statistically analyzed by the repeated measures ANOVA in conjunction with Tukey’s HSD. (GIR
was also separately analyzed with paired Student’s t-test). The results were considered significantly
different if p ≤ 0.05. To analyze the association between MCH vs. glucose, insulin and serum lipid
(total cholesterol, LDL-cholesterol, HDL-cholesterol and triglycerides) levels, “correlation” and “linear
regression” statistical methods were used.
5. Conclusions
Oral preparation of fenugreek seeds improves glucose metabolism by its insulin-sensitizing
effect and involves mechanisms that notably include fenugreek intake-related reduction of circulating
MCH levels. Since the fenugreek-associated increase in insulin-sensitivity was the most powerful in
patients with the lowest baseline GIR parameters, we conclude that it would be valued to repeat these
experiments on a larger number of patients who manifest T2DM. Our results presented here suggest
that members of MCH-related signal transduction pathways could become new molecular targets of
drug discovery and development in the future.
Supplementary Materials: The following are available online at www.mdpi.com/1422-0067/19/3/771/s1.
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